CGAS and multiple sclerosis: Furthermore, previous studies have reported that STING inhibition is an effective strategy for treating various inflammatory diseases in preclinical models, such as rheumatoid arthritis and multiple sclerosis.[64, 65] A recent clinical study has shown the efficacy of a cGAS‐STING inhibitor (VENT‐03) in attenuating autoimmune diseases, such as systemic lupus erythematosus.[66] However, the clinical efficacy of small molecule drugs is often compromised by their suboptimal targeting capabilities in vivo, leading to off‐target effects and reduced therapeutic effectiveness at inflamed sites.